wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q47102256-0FD79C7E-B8F5-4E33-8524-447B6F6238A4
Q47102256-0FD79C7E-B8F5-4E33-8524-447B6F6238A4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47102256-0FD79C7E-B8F5-4E33-8524-447B6F6238A4
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.
P2860
Q47102256-0FD79C7E-B8F5-4E33-8524-447B6F6238A4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47102256-0FD79C7E-B8F5-4E33-8524-447B6F6238A4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4f078b6eaf3ccea5560edc74550af43e3e95cfd7
P2860
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours